RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000083.xml
Synlett 2020; 31(16): 1573-1580
DOI: 10.1055/s-0040-1707139
DOI: 10.1055/s-0040-1707139
account
Leveraging Framework Instability: A Journey from Energy Storage to Drug Delivery
This work was supported by the United States Department of Energy (DE-SC0004888).Weitere Informationen
Publikationsverlauf
Received: 11. April 2020
Accepted after revision: 14. Mai 2020
Publikationsdatum:
18. Juni 2020 (online)
Abstract
Amorphous pharmaceuticals often suffer from poor physical stability, which can negate their high solubility, fast dissolution rate, and better oral bioavailability vs. crystalline forms. This represents a major hurdle to processing, storage, and delivery of amorphous pharmaceuticals. Several approaches to addressing these problems have been pursued, but there is still a need for a general method for stabilizing the amorphous form. We describe a novel approach using a water-unstable metal-organic framework as a drug delivery vehicle that demonstrates improved amorphous form stability accompanied by remarkably enhanced solubility and a fast dissolution rate. This research project spanned eleven years from conception to realization and dissemination. With origins in understanding the stability or porous solids for energy storage materials, the work also highlights potential of basic science understanding to illuminate new areas of application.
-
References and Notes
- 1a Department of Chemistry, University of Puerto Rico, San Juan, Puerto Rico, 00931, USA, and the Crystallization Design Institute at the Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico, 00926, USA.
- 1b Innovation Centre, Tata Chemicals Ltd, Ambedveth, Pune, Maharashtra, 412111, India.
- 1c Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
- 2 Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, Yliruusi J. Eur. J. Pharm. Biopharm. 2009; 71: 71
- 3 Alonzo DE, Zhang GG, Zhou D, Gao Y, Taylor LS. Pharm. Res. 2010; 27: 608
- 4 Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Pharm. Dev. Technol. 2011; 16: 187
- 5 Baird JA, Van Eerdenbrugh B, Taylor LS. J. Pharm. Sci. 2010; 99: 3787
- 6 Vasconcelos T, Sarmento B, Costa P. Drug Discovery Today 2007; 12: 1068
- 7 Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Chem. Commun. 2016; 52: 640
- 8 Seedher N, Kanojia M. Pharm. Dev. Technol. 2009; 14: 185
- 9 Serajuddin AT. J. Pharm. Sci. 1999; 88: 1058
- 10 Baghel S, Cathcart H, O’Reilly NJ. J. Pharm. Sci. 2016; 105: 2527
- 11 Yu L. Adv. Drug Delivery Rev. 2001; 48: 27
- 12a Frank DS, Matzger AJ. Mol. Pharmaceutics 2018; 15: 2714
- 12b Frank DS, Matzger AJ. Mol. Pharmaceutics 2019; 16: 682
- 12c Frank DS, Zhu Q, Matzger AJ. Mol. Pharmaceutics 2019; 16: 3720
- 13a Ha JM, Wolf JH, Hillmyer MA, Ward MD. J. Am. Chem. Soc. 2004; 126: 3382
- 13b Davey RJ, Schroeder SL, ter Horst JH. Angew Chem. Int. Ed. 2013; 52: 2166
- 13c Liu J, Nicholson CE, Cooper SJ. Langmuir 2007; 23: 7286
- 14 Cychosz KA, Matzger AJ. Langmuir 2010; 22: 17198
- 15 Guo P, Dutta D, Wong-Foy AG, Gidley DW, Matzger AJ. J. Am. Chem. Soc. 2015; 137: 2651
- 16 Ma J, Kalenak AP, Wong-Foy AG, Matzger AJ. Angew. Chem. Int. Ed. 2017; 56: 14618
- 17 Dodson RA, Matzger AJ. Chem. Mater. 2018; 30: 6559
- 18 Dodson RA, Matzger AJ. ACS Mater. Lett. 2019; 1: 344
- 19 The concept of reducing an invention to practice has explicit meaning in patents and named inventors must contribute to conception of an idea rather than merely reducing to practice. By contrast, in papers a high value is put on reduction to practice and often the first author is responsible for conducting most of the work even if they are minimally involved in conception.
- 20 Horcajada P, Serre C, Vallet-Regí M, Sebban M, Taulelle F, Férey G. Angew. Chem. Int. Ed. 2006; 45: 5974
- 21 Horcajada P, Serre C, Maurin G, Ramsahye NA, Balas F, Vallet-Regí M, Sebban M, Taulelle F, Férey G. J. Am. Chem. Soc. 2008; 130: 6774
- 22 Taylor KM, Rieter WJ, Lin W. J. Am. Chem. Soc. 2008; 130: 14358
- 23 Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, Eubank JF, Heurtaux D, Clayette P, Kreuz C, Chang J.-S, Hwang YK, Marsaud V, Bories P.-N, Cynober L, Gil S, Férey G, Couvreur P, Gref R. Nat. Mater. 2009; 9: 172
- 24 Della RJ, Liu D, Lin W. Acc. Chem. Res. 2011; 44: 957
- 25 Sun CY, Qin C, Wang CG, Su ZM, Wang S, Wang XL, Yang GS, Shao KZ, Lan YQ, Wang EB. Adv. Mater. 2011; 23: 5629
- 26 Cai W, Wang J, Chu C, Chen W, Wu C, Liu G. Adv. Sci. 2018; 6: 1801526
- 27 Almáši M, Zeleňák V, Palotai P, Beňová E, Zeleňáková A. Inorg. Chem. Commun. 2018; 93: 115
- 28 Tibbitt MW, Dahlman JE, Langer RS. J. Am. Chem. Soc. 2016; 138: 704
- 29 Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Chem. Rev. 1999; 99: 3181
- 30 Liechty WB, Krysciol DR, Slaughter BV, Peppas NA. Annu. Rev. Chem. Biomol. Eng. 2010; 1: 149
- 31 Langer RS, Peppas NA. Biomaterials 1981; 2: 201
- 32 Amidon GL, Lennernäs H, Shah VP, Crison JR. Pharm. Res. 1995; 12: 413
- 33a Sheehan RJ. Ullmann’s Encyclopedia of Industrial Chemistry, Vol. 35. Wiley-VCH; Weinheim: 2005: 639
- 33b Heck HD, Tyl RW. Regul. Toxicol. Pharmacol. 1985; 5: 294
- 34 Yamaguchi M. Mol. Cell Biochem. 2010; 338: 241
- 35 Suresh K, Matzger AJ. US 16668221, 2018
- 36 Suresh K, Matzger AJ. Angew. Chem. Int. Ed. 2019; 58: 16790
Current addresses:
We recently began exploring the ‘conventional’ approach of using organic polymers for this task with the added twist that we used postsynthetic functionalization of polymers in order to explore functional group effects in isolation: